Safety of anidulafungin in solid organ transplant recipients

J.M. Aguado, E. Varo, P. Usetti, J.C. Pozo, A. Moreno, M. Catalán, O. Len, M. Blanes, A. Solé, P. Muñoz, M. Montejo, the TOSCANA Study Group – 12 February 2012 – The aim of this study was the evaluation of the safety of anidulafungin in adult solid organ transplantation (SOT) recipients. During the study period (14 months), we included all consecutive SOT recipients from 14 centers who received anidulafungin for at least 48 hours for the treatment of invasive fungal infections (IFIs) or as prophylaxis. Relevant clinical and analytical information on clinical charts was reviewed.

Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection

Norah A. Terrault, Michelle E. Roland, Thomas Schiano, Lorna Dove, Michael T. Wong, Fred Poordad, Margaret V. Ragni, Burc Barin, David Simon, Kim M. Olthoff, Lynt Johnson, Valentina Stosor, Dushyantha Jayaweera, John Fung, Kenneth E. Sherman, Aruna Subramanian, J. Michael Millis, Douglas Slakey, Carl L. Berg, Laurie Carlson, Linda Ferrell, Donald M. Stablein, Jonah Odim, Lawrence Fox, Peter G.

Role of transcriptional and posttranscriptional regulation of methionine adenosyltransferases in liver cancer progression

Maddalena Frau, Maria L. Tomasi, Maria M. Simile, Maria I. Demartis, Fabiana Salis, Gavinella Latte, Diego F. Calvisi, Maria A. Seddaiu, Lucia Daino, Claudio F. Feo, Stefania Brozzetti, Giuliana Solinas, Satoshi Yamashita, Toshikazu Ushijima, Francesco Feo, Rosa M. Pascale – 9 February 2012 – Down‐regulation of the liver‐specific MAT1A gene, encoding S‐adenosylmethionine (SAM) synthesizing isozymes MATI/III, and up‐regulation of widely expressed MAT2A, encoding MATII isozyme, known as MAT1A:MAT2A switch, occurs in hepatocellular carcinoma (HCC).

Subscribe to